– UK, London – Turbine, the biological simulation company using AI to build predictive computational models of human cells and tissue, announced the appointments of Anna Marie Wagner, Dr. Greg Hersch (Ph.D.), and Alex Gwyther to its Board of Directors.
to its Board of Directors.
The updates to the company’s Board are as follows:
About Anna Marie Wagner
Anna Marie joins Turbine’s board as an Independent Director. She most recently served as SVP Head of AI, and Head of Corporate Development at Ginkgo Bioworks. In these roles, Anna Marie was responsible for artificial intelligence (AI) strategy, execution, and partnerships as well as all external innovation (whether via partnership or M&A). She also led Ginkgo’s public offering in 2021, raising $1.6 billion in the largest-ever go-public raise in biotech, and served as Ginkgo’s CFO during the pandemic. Previously, Anna Marie spent nearly a decade as an investor at Bain Capital Private Equity. She holds an M.B.A. from Harvard Business School and a B.A. in Applied Mathematics from Harvard College.
About Dr. Greg Hersch
Dr. Hersch is SVP of Enterprise Strategy and Venture at MSD (Merck & Co., Inc., Rahway, NJ USA). He has joined the board as an Observer on behalf of the MSD Global Health Innovation Fund, which co-led Turbine’s Series A financing.
About Alex Gwyther
Alex is an Investor at Mercia Ventures, which co-led Turbine’s Series A financing. He joins the board as an Investor Director. Alex joined Mercia in 2021 following four years at IBM’s consulting business, where he led business development efforts for the company’s AI, analytics, and blockchain solutions, among other technologies. He holds an M.S. in Science Communication from the Imperial College London and a B.A. in Biological Sciences from the University of Oxford. Alex replaces Daniela Tsoneva, Mercia’s prior representative on the Turbine Board.
About Turbine
Countless resources and time are expended globally to research and advance novel therapies that end in clinical failure and no patient benefit. Imagine a world where it is possible to predict any potential drug’s effect on translatable biological models yet unavailable for lab-based testing – while accurately representing patient biology. Turbine is revolutionizing the status quo by working to ensure that we always run the right wet lab experiments.
With machine learning that understands the logic by which human cells make decisions, Turbine has built the world’s leading predictive simulation of patient biology. The Simulated Cell platform models the foundational protein signaling logic that decides cell fate and facilitates in silico experiments at scales that are impossible in the physical world. Billions of simulated experiments can be run in the time it takes to complete even a single test in a wet lab to empower the biopharma industry by identifying and confirming disease-driving mechanisms.
Turbine’s platform is already used to guide the pipelines of leading pharma companies such as AstraZeneca, Ono Pharmaceutical, Cancer Research Horizons, and Bayer. In addition, Turbine has received funding from industry leaders such as MSD (Merck & Co., Inc., Rahway, NJ USA) Global Health Innovation Fund, MassMutual Ventures, Accel, and Delin Ventures among others.
For more information: https://turbine.ai/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.